Verubecestat
95%
- Product Code: 37702
CAS:
2095432-65-6
| Molecular Weight: | 523.43 g./mol | Molecular Formula: | C₁₉H₁₈F₅N₅O₅S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD28963974 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, store under inert gas |
Product Description:
Verubecestat is primarily investigated for its potential in treating Alzheimer's disease by inhibiting the beta-secretase enzyme, which plays a crucial role in the production of amyloid-beta peptides. These peptides are known to accumulate in the brains of Alzheimer's patients, forming plaques that are associated with the progression of the disease. By reducing the production of amyloid-beta, Verubecestat aims to slow down or potentially halt the neurodegenerative process. Clinical trials have explored its efficacy in improving cognitive function and delaying disease progression, although results have shown mixed outcomes. Despite setbacks in some studies, research continues to evaluate its potential benefits and safety profile in different patient populations and stages of Alzheimer's.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | ฿8,100.00 |
+
-
|
| 0.250 | 10-20 days | ฿16,191.00 |
+
-
|
Verubecestat
Verubecestat is primarily investigated for its potential in treating Alzheimer's disease by inhibiting the beta-secretase enzyme, which plays a crucial role in the production of amyloid-beta peptides. These peptides are known to accumulate in the brains of Alzheimer's patients, forming plaques that are associated with the progression of the disease. By reducing the production of amyloid-beta, Verubecestat aims to slow down or potentially halt the neurodegenerative process. Clinical trials have explored its efficacy in improving cognitive function and delaying disease progression, although results have shown mixed outcomes. Despite setbacks in some studies, research continues to evaluate its potential benefits and safety profile in different patient populations and stages of Alzheimer's.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :